A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort

Abstract

Background Antiretroviral therapy (ART) was rolled-out in Ethiopia in 2005, but there are no reports on outcome of ART and human immunodeficiency virus drug resistance (HIVDR) at national level. We described acquired drug resistance mutations in pol gene and performed a viral genome wide association study in virologic treatment failure patients who started first line ART during 2009–2011 in the first large countrywide HIV cohort in Ethiopia. Methods The outcome of tenofovir (TDF)- and zidovudine (ZDV)-based ART was defined in 874 ART naïve patients using the on-treatment (OT) and intention-to-treat (ITT) analyses. Genotypic resistance testing was done in patients failing ART (> 1000 copies/ml) at month 6 and 12. Near full-length genome sequencing (NFLG) was used to assess amino acid changes in HIV-1 gag , pol , vif , vpr , tat , vpu , and nef genes between paired baseline and month 6 samples. Results High failure rates were found in ITT analysis at month 6 and 12 (23.3%; 33.9% respectively). Major nucleoside and non-nucleoside reverse transcriptase (NRTI/NNRTI) drug resistance mutations were detected in most failure patients at month 6 (36/47; 77%) and month 12 (20/30; 67%). A high rate of K65R was identified only in TDF treated patients (35.7%; 50.0%, respectively). No significant difference was found in failure rate or extent of HIVDR between TDF- and ZDV- treated patients. All target regions of interest for HIVDR were described by NFLG in 16 patients tested before initiation of ART and at month 6. Conclusion In this first Ethiopian national cohort, a high degree of HIVDR was seen among ART failure patients, independent on whether TDF- or ZDV was given. However, the major reason to ART failure was lost-to-follow-up rather than virologic failure. Our NFLG assay covered all relevant target genes for antiretrovirals and is an attractive alternative for HIVDR surveillance. Electronic supplementary material The online version of this article (10.1186/s12879-019-4196-8) contains supplementary material, which is available to authorized users.

Drug Resistance and Its Related Factors in ART-failure Patients From 2018 to 2019 in Liaoning Province, China

“…The high prevalence of DR in NNRTIs may related to widespread use of efavirenz in the initial regimen in this study. Of concern, 50.39% participants in our study showed dual-class resistance (NNRTIs and NRTIs), which was similar to the patterns of studies reported from other studies from low and middle-income countries [27][28][29].…”

Profile of HCV Genotypes and Hiv-Subtypes Among Hiv-Coinfected Patients in Southern Brazil

“…Proviral HIV-1 RNA was extracted from serum samples using the QIAamp Viral RNA mini Kit ® (Qiagen, Hilden, Germany) following the manufacturer's instructions, and the cDNA was sequentially obtained using the Superscript III RT-PCR kit (Invitrogen, CA). Fragments of the pol gene were generated by PCR according to a previously reported (18,19) . Strict laboratory precautions were taken to avoid cross contamination.…”

Seroprevalence of hepatitis B and C virus among highly active antiretroviral therapy experienced children in Gondar, Ethiopia

“…The national HIV treatment guideline requests screening for baseline HBV serology (HBsAg) [ 25 ] But HBV diagnosis before initiation of HIV treatment and close monitoring of patients on for HBV viremia and biochemical status are not implemented in Ethiopia. Mutation and rapid progression of drug resistance, exacerbation of HBV disease and liver enzyme flare are the potential risks in this high HIV/HBV burden area [ 26 , 27 ]. This study did not assess the effect of 3TC because all the study participants were exposed to the drug, tested once and not followed for HBV response.…”